CONMED (CNMD) Q3 2026 Earnings Call Transcript

CONMED (CNMD) reported Q3 2026 net revenue of $335.6M, with organic growth of 6.7% YoY. Adjusted EPS was $1.04, exceeding expectations. AirSeal and Buffalo Filter drove sales growth, with AirSeal showing strong performance in robotic and laparoscopic surgery. The company remains optimistic about long-term growth prospects for these products.

Original reporting
Published Oct 29, 2026, 4:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CONMED (CNMD) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CNMDNeutralMed
01

Why it matters

The earnings release adds fresh quantitative data for valuation models and may influence short‑term price action.

02

Market read

Primary relevance to CNMD shareholders; secondary relevance to med‑tech sector and competitors.

03

What to watch

Potential upside from new AirSeal indication and upcoming regulatory approvals not reflected in current numbers.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Conmed (CNMD) presented its Q3 2026 earnings call, highlighting revenue, EPS, product updates, and strategic initiatives.

Company-level read

Ticker impact

$CNMDNeutralHigh confidence
Context

Q3 2026 earnings call disclosed net revenue of $335.6M and adjusted EPS of $1.04, the first public release of these figures.

Expected impact

likely limited upside pressure as results meet guidance, but no major catalyst for a sharp move

Evidence & confidence

First report of earnings provides fresh data; market reaction expected to be muted given modest scale.

Market effects

Provides a data point for the medical device sector, especially surgical equipment manufacturers.

Limited to US and international markets where Conmed sells its products.

Low global impact; primarily relevant to investors in small‑cap med‑tech stocks.

Counterpoint

Despite earnings beat, the modest revenue growth and narrow product focus could limit upside.

Key entities

  • Conmed

    Medical device manufacturer reporting Q3 2026 results.

  • Intuitive Surgical

    Partner in AirSeal robotic indication.

Related articles

$CNMDMedAI 8/10

CNMD Q3 deep dive: stable revenue, margin improvement, and focus on core growth platforms

CONMED reported Q3 revenue of $335.6M, matching estimates, with adjusted EPS of $1.04, beating estimates by 3.7%. Adjusted EBITDA was $67.88M, a 2.9% beat. The company reconfirmed revenue guidance of $1.36B and raised adjusted EPS guidance to $4.58. Operating margin improved to 11.1%. International sales and AirSeal platform growth drove performance, while U.S. orthopedic sales declined.

$CNMDMed

Conmed Corp (CNMD) Q3 2026 Earnings Call Highlights: Solid Organic Growth Offset

Conmed Corp (CNMD) reported Q3 2026 earnings with global general surgery up 6.4% and orthopedics up 7.2%. U.S. general surgery grew 2%, while U.S. orthopedics declined slightly. CEO Pat Beyer highlighted strong performance in AirSeal and direct smoke evacuation, but noted variability in OEM business. CFO John Gallagher adjusted the organic growth range to 5.5% due to international performance. AirSeal grew in high single-digit to low double-digit range.

$CNMDHighAI 8/10

CONMED Q3 Earnings Call Highlights

CONMED reported Q3 organic revenue growth of 7.2% in orthopedic surgery, driven by international demand and BioBrace. Adjusted gross margin increased to 56.4%. The company updated its 2026 outlook, narrowing revenue growth to 5%-5.5% and raising adjusted EPS guidance to $4.54-$4.61. CONMED repurchased 1.2 million shares and expects to allocate $62 million to buybacks for the year.

$CNMDMedAI 8/10

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) reported Q3 earnings of $1.04 per share, beating estimates by $0.04. Revenue was $335.56M, missing estimates by 0.37%. The company has beaten EPS estimates four times in the last four quarters. Shares are up 16.3% YTD. The Zacks Rank for the stock is #3 (Hold).

$CNMDHighAI 8/10

CONMED (NYSE:CNMD) posts Q3 2026 sales in line with estimates

CONMED (CNMD) reported Q3 2026 revenue of $335.6M, flat year-on-year but in line with estimates. Adjusted EPS of $1.04 beat estimates by 3.7%. The company reconfirmed its full-year revenue guidance of $1.36B and slightly raised its EPS guidance to $4.58. Operating margin decreased to 11.1% from 3.5% year-on-year. Long-term revenue growth has slowed, with a 6.7% CAGR over five years.